Suvoda has bagged $40 million to revolutionize clinical trials and expand its product offerings.
FREMONT, CA: Suvoda is a SaaS provider of clinical trial software that has bagged a $40 million equity investment from LLR Partners that is a Philadelphia-based private equity firm. LLR's investment is a novel institutional capital funded in Suvoda that will be used to assist in establishing the company's continued expansion and the growth of its product offerings. Suvoda offers a strong SaaS solution that supports pharmaceutical and biotechnology businesses to manage sophisticated trial designs. The company helps in optimizing the supply chain beyond the clinical trial continuum, from small investigator-sponsored trials to important global Phase III studies.
Suvoda has turned into a multi-national organization in the U.S. and Europe, helping customers and end-users in 62 countries. The organization is delighted to have teamed-up with LLR Partners, shifting towards growth. The SaaS provider of clinical trial software is centered on revolutionizing clinical trials using the potential of technology. Suvoda's Interactive Response Technology (IRT) system solves complicated patient randomization and clinical trial supply chain difficulties. This round of investment will concentrate on advancing best-in-class functionality, empowering users to expect the unexpected in their clinical program assuredly.
Suvoda is a novel SaaS firm concentrated on transforming clinical trials with the use of the power of technology. The company solves sophisticated patient randomization and clinical supply chain difficulties. Suvoda's IRT operation with Trial Intelligence offers pace, agility, and insight to manage the most complicated clinical trial efficiency. Its Drug Inventory Management System (DIMS) is created for inventory management and supply chain for simple trials that do not require patient management.